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We would like to congratulate the ADSORB trialists with the
initiative of the much awaited trial on management of acute type
B aortic dissections. Many of us in the vascular community are
looking forward to hearing the answers ADSORB set out to provide.
The trial design printed in this Journal is well written, but it does
raise a few methodological questions.
Firstly, the primary endpoint of this study comprises
a composite of aortic rupture, aortic dilatation and/or observation
of blood ﬂow in the false lumen. However, aortic dilatation and
complete false lumen thrombosis (surrogates of aortic remodelling)
correspond to outcomes on imaging studies, but their true clinical
signiﬁcance is not completely understood.1,2 Consequently, this
study may fail to answer the question of added clinical beneﬁt from
stent grafting acute uncomplicated dissections.
Also, bias may be introduced by the endpoint deﬁnitions. For
instance, complete false lumen thrombosis, is deﬁned as total
thrombosis of the descending thoracic false lumen for the medical
therapy arm. In the stent group, however, complete thrombosis is
deﬁned as thrombosis of only the segment parallel to the stent
graft, excluding the last 2 cm, meaning the remainder of the false
lumen may be patent. Since the lamella is slim and mobile in the
(sub)acute stages, implantation of a correctly sized endograft
would expectantly compress the majority of the false lumen, as
conﬁrmed by INSTEAD.3 It is doubtful that medical therapy alone
will result in false lumen collapse. Since this is the “driving force”DOI of original article: 10.1016/j.ejvs.2012.03.023.
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to favour stengrafting.
Finally, a reﬂection is required regarding the dramatic change in
sample size, based on data from false lumen thrombosis (which
was published long after the initial ADSORB-trial design). Is a trial
still required to show such a large difference in the rates of false
lumen thrombosis in medical vs. stent graft groups (target effect
size ¼ 0.58)? In other words, is there still equipoise to justify
a randomized trial? Naturally, if more “conventional” endpoints
had been chosen (such as long-term freedom from rupture,
dissection-related complications, re-intervention or death) much
larger numbers would be required, but more deﬁnitive and clini-
cally relevant data would be obtained.
The vascular community is eagerly looking for ﬁnal answers on
how to manage uncomplicated type B dissections, but it is still
unclear if ADSORB will deliver these.References
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